Theravance settles YUPELRI patent litigation with Teva; generic launch delayed to April 2039

Theravance Biopharma, Inc.

Settlement with Teva resolves ANDA litigation; Teva gets license to launch generic on or after April 23, 2039.
License is royalty-free, non-exclusive, non-sublicensable; subject to DOJ/FTC review and customary exceptions.
Litigation against six other ANDA filers (Accord, Cipla, Eugia, Lupin, Mankind, Orbicular) remains pending.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.